Arcadia Biosciences, Inc. (RKDA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcadia Biosciences, Inc. on September 4, 2026, regarding an event dated August 31, 2026. The Company is a Delaware corporation with its principal executive offices in Dallas, Texas. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "RKDA".
Key Financial Metrics
The filing references financial data from the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2026.
- Stockholders' Equity: $633,000 (as of June 30, 2026).
- Nasdaq Minimum Requirement: $2,500,000 (per Listing Rule 5550(b)(1)).
- Compliance Status: The Company failed to meet the minimum stockholders' equity requirement. The filing states the Company also does not meet alternative listing standards regarding market value of listed securities or net income from continuing operations.
- Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
On August 31, 2026, the Company received a notification from Nasdaq stating it is no longer in compliance with continued listing rules due to insufficient stockholders' equity. While the stock continues to trade on the Nasdaq Capital Market, the Company faces potential delisting if compliance is not restored.
Outlook, Management Commentary, and Risks
Compliance Plan and Timeline:
- The Company has 45 calendar days (until October 15, 2026) to submit a plan to Nasdaq to achieve and sustain compliance.
- If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
- The Company is currently evaluating alternatives to regain compliance.
- There is no assurance that Nasdaq will accept the Company's plan or that the Company will achieve compliance during any extension period.
- If the plan is rejected, the Company may appeal to a Nasdaq Hearings Panel, which would stay delisting actions pending a decision, though success is not guaranteed.
- Forward-looking statements regarding the ability to access capital and regain compliance are subject to significant risks and uncertainties.
Key Facts for Investor Verification
- Verify the Company's stockholders' equity of $633,000 reported in the June 30, 2026 Form 10-Q.
- Monitor the submission of a compliance plan to Nasdaq by the October 15, 2026 deadline.
- Assess the likelihood of Nasdaq accepting the proposed plan and granting an extension.
- Review the Company's ability to raise capital to meet the $2.5 million equity threshold.
- Check for any subsequent filings regarding the outcome of the compliance plan or appeal process.